AKBA
HealthcareAkebia Therapeutics, Inc.
$1.51
$-0.04 (-2.58%)
Jan 5, 2026
Price History (1Y)
Analysis
Akebia Therapeutics, Inc. is a company in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. With a market capitalization of $400.70M and revenue of $225.07M (TTM), it operates on a relatively large scale with 181 employees. The company's financial health appears to be mixed. Profitability metrics show an operating margin of 7.6% and a gross margin of 83.3%, but the net income is -$15,905,000 (TTM). Returns are somewhat stable, with a return on assets of 4.8%. However, the balance sheet reveals significant debt ($199.01M) compared to cash ($166.44M), resulting in a debt-to-equity ratio of 478.48. Akebia Therapeutics' valuation is characterized by a forward price-to-earnings ratio of 8.88 and an EV/EBITDA of 13.77. Revenue growth has been substantial, with a year-over-year increase of 57.0%, but earnings growth data is not available. The company does not offer dividends, resulting in a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $400.70M
- P/E Ratio
- N/A
- 52-Week High
- $4.08
- 52-Week Low
- $1.45
- Avg Volume
- 4.16M
- Beta
- 0.35
Company Info
- Exchange
- NCM
- Country
- United States
- Employees
- 181